- Home
- INKT vs GDTC Comparison
INKT vs GDTC Comparison
Compare INKT & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- GDTC
- Stock Information
- Founded
- INKT 2017
- GDTC 2018
- Country
- INKT United States
- GDTC Singapore
- Employees
- INKT N/A
- GDTC N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- GDTC Health Care
- Exchange
- INKT Nasdaq
- GDTC Nasdaq
- Market Cap
- INKT 36.7M
- GDTC 29.4M
- IPO Year
- INKT 2021
- GDTC 2023
- Fundamental
- Price
- INKT $8.43
- GDTC $2.69
- Analyst Decision
- INKT Strong Buy
- GDTC Buy
- Analyst Count
- INKT 2
- GDTC 1
- Target Price
- INKT $19.50
- GDTC $5.00
- AVG Volume (30 Days)
- INKT 11.3K
- GDTC 11.3K
- Earning Date
- INKT 03-18-2025
- GDTC 01-01-0001
- Dividend Yield
- INKT N/A
- GDTC N/A
- EPS Growth
- INKT N/A
- GDTC N/A
- EPS
- INKT N/A
- GDTC N/A
- Revenue
- INKT N/A
- GDTC $330,254.00
- Revenue This Year
- INKT N/A
- GDTC $14.71
- Revenue Next Year
- INKT N/A
- GDTC N/A
- P/E Ratio
- INKT N/A
- GDTC N/A
- Revenue Growth
- INKT N/A
- GDTC N/A
- 52 Week Low
- INKT $4.56
- GDTC $1.20
- 52 Week High
- INKT $19.00
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- INKT 41.71
- GDTC 46.11
- Support Level
- INKT $7.54
- GDTC $2.61
- Resistance Level
- INKT $8.88
- GDTC $2.80
- Average True Range (ATR)
- INKT 0.86
- GDTC 0.18
- MACD
- INKT -0.25
- GDTC -0.02
- Stochastic Oscillator
- INKT 6.05
- GDTC 51.28
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.